Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Tuesday, September 29, 2009

2006 paper : FMO3 'in action'

FMO3 is always of great interest to the blog, since it is one of the group of 'xenobiotic metabolizing enzymes' that deal with both external (xenobiotic) and internal compounds, either to neutralize for excretion or to 'activate' if needed in the main circulation. All the xenobiotic metabolizing enzymes are suspects in metabolic body odor, but FMO3 in particular since it is known to cause trimethylaminuria and also deals with 1,000s of smelly sulfide, amine and phosporous containing compounds.

In this 2006 paper, it looks as if this was the first time that FMO3 was finally 'seen in action' (i.e. it is finally demonstrated how it oxidizes a compound ... the reaction). Most readers know that the enzyme is dependent on vitamin B2 (riboflavin, as part of the FAD), but this paper explains in depth that it is also dependent on NADPH which itself uses niacin (vitamin B3) as a cofactor. This does not mean that niacin is likely to be of any benefit, and niacin itself can cause quite an undesirable symptom when taken as a supplement (the niacin flush, as well as a feeling of unease). There has been mention of cases where the FMO3 enzyme 'failure' is at the NADPH stage, but for the moment it is not known if this is of any significance.

Full paper 2006 : Mechanism of action of a flavin-containing monooxygenase

Interesting quotes from the paper :

Elimination of nonnutritional and insoluble compounds is a critical task for any living organism. Flavin-containing monooxygenases (FMOs) attach an oxygen atom to the insoluble nucleophilic compounds to increase solubility and thereby increase excretion...

... Flavin-containing monooxygenases (FMOs) and cytochromes P450 are two important microsomal (i.e. liver) proteins involved in the process of nonnutritional foreign compounds metabolism known as xenobiotics. Their main function is to add molecular oxygen to lipophilic compounds, making them soluble to ensure rapid excretion. FMOs oxygenate nucleophilic O, N, S, and Se atoms of a wide range of substrates, such as amines, amides, thiols, and sulfides...

...The mammalian FMO gene family contains five similar genes (FMO1 through FMO5). FMO1 and FMO3 are prominent isoforms expressed mainly in liver microsomes and in other tissues. FMO1 expression is higher in fetal liver, whereas FMO3 is more abundant in adult human. FMO2 is expressed in the lungs of nonhuman primates; FMO4 and FMO5 represent scarce isoforms (5, 6). Individuals with defective FMOs exhibit “fish odor syndrome” caused by excretion of trimethylamine instead of its oxygenated form, trimethylamine N-oxide in urine, sweat, and breath...

...Cytochrome P450s contain heme as a prosthetic group, whereas FMOs use FAD. These proteins need a cofactor NADPH in addition to the prosthetic group to accomplish their functional goal...

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory, the New York Structural Biology Center, and SGX Pharmaceuticals, Inc., have determined the atomic crystal structure and functional mechanism of an enzyme essential for eliminating unwanted, non-nutritional compounds such as drugs, industrial chemicals, and toxic compounds from the body...

..."For FMOs, the end result -- that an oxygen atom gets added to make these compounds soluble -- is simple," Swaminathan says...

...People with defective FMOs might also suffer additional side effects from drugs, industrial compounds, or other chemicals.


Post a Comment